Bellicum Pharmaceuticals closes $34.4 mln in Series B financing
Bellicum Pharmaceuticals said Tuesday that it has raised an additional $14.7 million in its Series B round, bringing the tally to $34.4 million. Investors included AVG Ventures and Remeditex Ventures. Based in Houston, Texas, Bellicum develops cell therapies that treat cancers and other life-threatening diseases.
7 January 2014•2 mins read
